equin
herpesviru
type
major
caus
respiratori
neurolog
reproduct
diseas
hors
worldwid
member
alphaherpesvirina
close
relat
caus
agent
human
chicken
poxshingl
varicella
zoster
viru
vzv
well
cold
sore
genit
herp
herp
simplex
type
spread
respiratori
secret
replic
nasal
epithelium
upon
gain
access
respiratori
tract
initi
replic
follow
leukocyteassoci
viremia
replic
occur
endothelia
blood
vessel
central
nervou
system
cn
uteru
vascul
lead
myeloencephalopathi
abort
respect
establish
latenc
neural
lymphoid
tissu
recrudesc
time
stress
transport
pregnanc
competit
race
therefor
hors
travel
competit
come
contact
new
anim
risk
shed
contract
viru
make
viral
infect
huge
concern
perform
hors
industri
recent
increas
occurr
neurolog
outbreak
especi
neurolog
form
diseas
report
outbreak
frequent
associ
high
mortal
rate
consequ
recent
classifi
potenti
emerg
diseas
us
depart
agricultur
unfortun
vaccin
current
form
control
avail
vaccin
provid
complet
protect
protect
immun
shortliv
vaccin
repeat
least
everi
month
howev
continu
outbreak
involv
larg
number
anim
rais
question
whether
repeat
vaccin
suffici
protect
anim
outbreak
situat
moreov
repeat
vaccin
recent
suggest
predispos
hors
develop
sever
form
infect
myeloencephalopathi
treatment
infect
reduc
symptomat
care
experiment
antivir
drug
yet
prove
clinic
efficaci
exampl
drug
acyclovir
valacyclovir
shown
seriou
limit
due
poor
bioavail
high
therapeut
concentr
need
order
reach
desir
effect
make
drug
costli
medic
question
efficaci
rna
interfer
mediat
small
interf
rna
sirna
import
defens
mechan
viral
infect
plant
sirna
recent
intens
examin
abil
prevent
andor
treat
viral
infect
sirna
bind
complementari
target
mrna
upon
interact
cellular
rna
interfer
mechan
specif
target
sequenc
degrad
result
inhibit
protein
express
synthet
sirna
shown
success
inhibit
viral
replic
sever
virus
among
herpesvirus
addit
sirna
respiratori
virus
test
extens
anim
model
demonstr
sirna
effect
inhibit
replic
sar
coronaviru
rhesu
macaqu
addit
intranas
administ
sirna
target
viral
gene
parainfluenza
viru
respiratori
syncyti
viru
shown
effect
prevent
pulmonari
diseas
patholog
mice
present
studi
evalu
use
sirna
therapi
limit
prevent
infect
vitro
murin
model
infect
synthet
sirna
design
two
essenti
highli
conserv
gene
firstli
open
read
frame
orf
encod
envelop
glycoprotein
b
gb
chosen
glycoprotein
essenti
viral
entri
celltocel
spread
secondli
sirna
encod
originbind
protein
ori
helicas
design
protein
essenti
initi
herpesvir
genom
replic
glycoprotein
b
gb
envelop
protein
essenti
viral
entri
cell
celltocel
spread
originbind
protein
ori
helicas
enzym
necessari
genom
replic
chosen
possibl
target
rna
interfer
sirna
protein
synthes
evalu
effect
reduc
replic
direct
gb
mrna
effici
reduc
viral
replic
dosedepend
manner
reduct
viral
titer
observ
low
pmol
p
reach
steadyst
level
start
pmol
reduct
viral
titer
p
figur
treat
cell
direct
ori
helicas
mrna
result
reduct
viral
titer
concentr
rang
pmol
p
furthermor
sirna
also
abl
significantli
reduc
plaqu
size
reduct
total
plaqu
area
pmol
use
p
figur
evalu
sirna
transfect
effici
cell
transfect
commerci
avail
sigfp
sirna
target
egfp
gene
egfpexpress
strain
use
vitro
studi
egfp
express
allow
readi
identif
infect
cell
virusinduc
plaqu
pretreat
cell
pmol
sigfp
effici
reduc
egfp
express
infect
cell
figur
without
effect
infect
ie
plaqu
size
titer
remain
unaffect
even
though
egfp
express
longer
detect
figur
ensur
sirna
transfect
neg
effect
infect
cell
treat
pmol
neg
control
sirna
siluc
sirna
target
luciferas
gene
infect
expect
express
luciferas
observ
effect
egfp
express
figur
viral
infect
compar
mocktreat
cell
figur
assess
effect
mrna
level
rel
quantit
two
mrna
perform
use
quantit
revers
transcriptas
pcr
qrtpcr
h
pi
rel
quantiti
gb
ori
mrna
reduc
follow
treatment
respect
compar
untreat
cell
p
figur
signific
differ
gb
ori
mrna
level
cell
observ
untreat
cell
cell
treat
control
sirna
siluc
figur
ii
control
sirna
sigfp
siluc
data
shown
effect
silenc
gb
also
evalu
protein
level
western
blot
analysi
use
antigb
antibodi
clear
reduct
protein
express
observ
cell
treat
compar
nontreat
cell
cell
treat
control
siluc
sirna
figur
mockinfect
cell
express
gb
control
antibodi
show
equal
amount
cell
protein
load
lane
figur
conclud
data
sirna
treatment
target
gb
ori
significantli
reduc
infect
effect
silenc
gb
ori
express
mrna
protein
level
silenc
two
essenti
protein
result
significantli
reduc
viral
titer
plaqu
size
next
seri
experi
repeat
treatment
use
combin
two
sirna
appli
togeth
show
effect
reduc
infect
much
lower
concentr
either
sirna
seen
figur
reduct
viral
titer
observ
treatment
either
pmol
pmol
also
obtain
use
combin
pmol
pmol
p
surprisingli
combin
higher
concentr
eg
pmol
pmol
less
effect
reduc
viral
titer
lower
concentr
pmol
figur
observ
also
report
sirna
combin
human
respiratori
virus
inhibitori
activ
one
sirna
inhibit
use
high
amount
anoth
sirna
time
known
cell
limit
capac
assembl
rnainduc
silenc
complex
risc
onto
transfect
sirna
sirna
differ
specif
effici
risc
target
possibl
explan
could
therefor
sirna
compet
avail
risc
pool
present
cell
inhibit
higher
concentr
effect
pmol
combin
cocktail
gb
silenc
also
evalu
qrtpcr
western
blot
analysi
result
similar
observ
describ
pmol
data
shown
data
indic
target
multipl
gene
simultan
effect
reduc
viral
replic
one
gene
target
significantli
lower
concentr
individu
sirna
final
last
set
vitro
experi
evalu
efficaci
sirna
addit
function
time
cell
transfect
sirna
differ
time
point
h
simultan
h
infect
observ
pmol
could
significantli
reduc
viral
replic
appli
time
h
prior
h
infect
p
figur
concentr
pmol
reduc
viral
titer
significantli
transfect
infect
occur
simultan
transfect
h
infect
p
figur
combin
pmol
significantli
decreas
viral
titer
time
point
test
p
except
h
infect
figur
signific
differ
time
point
test
control
treatment
includ
cell
treat
sigfp
siluc
sirna
data
shown
taken
togeth
vitro
experi
clearli
show
sirna
treatment
effect
reduc
replic
use
infect
effici
even
appli
onset
replic
effici
sirna
therapi
vitro
clearli
show
cellular
replic
spread
prevent
cell
cultur
murin
model
use
assess
whether
sirna
treatment
also
effect
vivo
mous
model
infect
first
describ
awan
et
al
intens
use
predict
efficaci
put
vaccin
hors
well
virul
potenti
sever
strain
present
studi
mice
anaesthet
inocul
intranas
sirna
follow
infect
pfu
rout
amount
combin
sirna
use
well
time
point
sirna
treatment
infect
summar
tabl
initi
experiment
set
sirna
treatment
given
alon
combin
h
h
infect
evalu
mice
per
group
treat
control
sirna
siluc
began
lose
weight
earli
day
pi
continu
lose
weight
day
pi
maximum
weight
loss
origin
bodi
weight
observ
preinfect
weight
regain
day
pi
figur
result
compar
obtain
mice
receiv
sirna
transfect
reagent
lipofectamin
infect
data
shown
mice
treat
sirna
target
gene
h
infect
also
lost
weight
first
day
pi
weight
loss
reach
maximum
mice
treat
pmol
combin
pmol
pmol
respect
mice
treat
pmol
pmol
regain
origin
bodi
weight
day
pi
mice
treat
pmol
day
pi
figur
group
treat
pmol
lost
bodi
weight
took
day
pi
regain
preinfect
weight
howev
mice
start
regain
weight
alreadi
day
pi
contrast
control
siluc
treat
group
mice
nt
start
regain
weight
day
pi
differ
mice
treat
control
sirna
transfect
reagent
alon
statist
signific
day
pi
nonparametr
statist
test
p
figur
uninfect
control
group
show
weight
loss
indic
repeat
anesthesia
protocol
use
intranas
applic
sirna
viru
effect
weight
loss
figur
sinc
bodi
weight
loss
caus
infect
strongli
associ
inflammatori
respons
lung
infect
mice
valid
data
weight
loss
histopatholog
analys
lung
tissu
obtain
day
pi
lung
mice
treat
control
siluc
pronounc
hyperplasia
bronchiolar
epithelium
day
pi
necrot
cell
airway
lumina
inclus
bodi
well
signific
interstiti
inflamm
figur
c
lung
mice
treat
slightli
less
affect
lung
mice
treat
combin
clearli
less
affect
compar
siluc
control
group
figur
c
regard
viru
titer
mice
inocul
control
siluc
titer
around
pfumg
lung
tissu
day
pi
figur
contrast
viru
titer
lung
mice
treat
h
infect
either
alon
variou
combin
show
signific
reduct
viral
titer
averag
pfumg
lung
tissu
student
ttest
p
figur
similar
reduct
viru
titer
observ
day
pi
although
declin
viru
titer
day
gener
indic
begin
clearanc
viru
infect
data
shown
treatment
sirna
target
gene
h
infect
also
show
reduct
bodi
weight
loss
viru
titer
extent
compar
control
sirna
group
albeit
without
reach
statist
signific
infect
mice
show
maxim
weight
loss
day
pi
around
group
mice
receiv
control
siluc
mice
treat
sirna
gene
addit
origin
bodi
weight
regain
day
earlier
treat
group
compar
mice
treat
control
siluc
preinfect
weight
reach
late
day
pi
titer
pfumg
lung
tissu
observ
siluctr
group
slightli
higher
lung
mice
treat
pfumg
pfumg
combin
pfumg
pfumg
pmol
pmol
respect
taken
togeth
first
vivo
experi
clearli
reveal
sirna
therapi
effect
vivo
reduc
clinic
symptom
challengeinfect
anim
capabl
significantli
reduc
inflamm
viral
replic
target
organ
lung
least
appli
h
infect
sinc
describ
previous
sirna
applic
mucos
surfac
vivo
requir
transfect
vehicl
second
experi
mice
perform
without
transfect
agent
addit
extrapol
previou
find
time
point
includ
sirna
treatment
h
h
infect
sirna
combin
pmol
evalu
sinc
treatment
group
shown
significantli
reduc
weight
loss
viru
replic
first
observ
intranas
applic
requir
transfect
reagent
signific
differ
weight
loss
data
shown
viral
titer
student
ttest
p
figur
observ
sirna
deliv
either
lipofectamin
pb
secondli
observ
sirna
treatment
h
infect
effect
significantli
reduc
weight
loss
nonparametr
statist
test
p
data
shown
viru
replic
lung
student
ttest
p
figur
treatment
pmol
h
infect
significantli
reduc
weight
loss
data
shown
howev
signific
reduct
viru
titer
lung
day
pi
observ
mice
student
ttest
p
figur
lastli
third
experi
conduct
evalu
effect
sirna
treatment
infect
mice
per
group
infect
follow
sirna
inocul
h
infect
control
group
consist
untreat
infect
mice
could
never
observ
signific
differ
untreat
siluctr
mice
previou
experi
viral
load
lung
determin
viral
titrat
qpcr
five
mice
per
group
day
pi
amount
infecti
viru
determin
viru
isol
lung
mice
treat
sirna
h
infect
significantli
reduc
student
ttest
p
compar
untreat
infect
anim
figur
signific
reduct
viru
titer
observ
anim
treat
sirna
h
post
infect
p
reduct
viral
genom
copi
lung
infect
mice
observ
h
pi
reduct
reach
statist
signific
group
mice
treat
sirna
h
post
infect
student
ttest
p
figur
data
show
treatment
sirna
infect
also
effici
reduc
replic
therefor
indic
potenti
sirna
treatment
outbreak
sever
individu
might
alreadi
expos
viru
cours
past
year
much
progress
made
evalu
rna
interfer
novel
potent
therapi
fight
number
viru
infect
man
anim
progress
led
seriou
promis
term
drug
develop
use
small
interf
si
rna
technolog
intranas
applic
exampl
intranas
sirna
applic
respiratori
syncyti
viru
rsv
recent
enter
phase
clinic
trial
shown
sirna
safe
well
toler
healthi
volunt
area
research
fill
therapeut
void
provid
evid
sirna
possibl
develop
treatment
andor
prevent
option
respiratori
virus
otherwis
difficult
control
present
studi
describ
use
sirna
import
respiratori
pathogen
hors
alphaherpesviru
equin
herpesviru
type
major
pathogen
defi
control
measur
demonstr
increas
sever
often
fatal
diseas
outbreak
occur
despit
vaccin
sirna
direct
highli
conserv
essenti
gene
shown
vitro
set
significantli
reduc
viral
replic
measur
signific
reduct
number
size
plaqu
result
indic
select
sirna
interf
infect
capabl
decreas
viru
spread
neighbor
uninfect
cell
applic
sirna
readili
effect
combin
signific
reduct
infect
alreadi
observ
littl
pmol
sirna
per
cell
ml
cultur
medium
use
interestingli
effect
concentr
sirna
far
vitro
sirna
concentr
describ
respiratori
pathogen
like
rsv
parainfluenza
viru
sar
coronaviru
indic
potenc
select
sirna
gene
test
studi
use
wellestablish
vivo
murin
model
infect
also
abl
demonstr
mice
treat
intranas
sirna
protect
clinic
sign
like
weight
loss
importantli
viral
load
lung
treat
mice
significantli
lower
assess
viral
titrat
lung
tissu
ii
quantit
realtim
pcr
iii
histolog
evalu
inclus
bodi
addit
histolog
evalu
infect
lung
tissu
mice
treat
control
sirna
direct
luciferas
show
extens
perivascular
cuf
well
interstiti
inflammatori
inflamm
contrast
significantli
less
inflammatori
infiltr
vascular
chang
observ
mice
treat
sirna
specif
target
gene
anoth
promis
result
initi
vivo
mice
studi
signific
differ
could
observ
effect
sirna
complex
transfect
reagent
lipofectamin
buffer
pb
agre
previou
report
strong
activ
intranas
administ
nake
sirna
demonstr
variou
anim
model
one
concern
use
rna
interfer
virus
escap
sirna
mutat
target
sequenc
sirna
pressur
mutat
chang
report
rna
virus
like
human
immunodefici
hepat
c
viru
escap
mutat
found
upon
sirna
treatment
herpesvirus
like
also
present
studi
sequenc
analysi
viral
dna
isol
lung
infect
mice
show
mutat
target
gb
ori
gene
data
shown
indic
escap
mutat
might
concern
dna
virus
addit
use
combin
sirna
two
differ
essenti
gene
herebi
reduc
likelihood
escap
mutat
anoth
concern
rais
question
whether
effect
observ
upon
sirna
addit
caus
induct
immun
respons
eg
respons
upon
deliveri
nucleic
acid
specif
action
chosen
sirna
focu
extens
potenti
induct
innat
immun
respons
follow
applic
sirna
howev
previous
report
interferon
respons
mostli
occur
vitro
depend
transfect
reagent
actual
sirna
addit
sever
vivo
studi
includ
one
assess
intranas
appli
sirna
rsv
unabl
reveal
sirnainduc
interferon
respons
data
led
us
assum
induct
innat
immun
respons
upon
intranas
administr
sirna
gene
would
also
unlik
furthermor
control
sirna
siluc
sigfp
fail
silenc
effect
lend
addit
support
notion
observ
effect
use
gb
orispecif
sirna
inde
specif
major
bottleneck
develop
sirna
therapi
optim
potenc
halflif
sirna
order
efficaci
realist
clinic
set
modif
optim
like
depend
clinic
indic
strategi
use
deliv
sirna
exampl
incorpor
complex
particl
shown
offer
quit
variabl
protect
sirna
exposur
endogen
nucleas
therefor
unmodifi
sirna
may
particularli
use
situat
longterm
silenc
requir
treat
acut
viral
infect
human
anim
notabl
mani
vivo
studi
shown
diseas
protect
use
unmodifi
sirna
optim
halflif
similar
data
manuscript
exampl
great
interest
potenti
develop
sirna
drug
candid
rsv
clinic
trail
demonstr
low
dosag
inhal
uncomplex
sirna
potent
easi
way
administ
antivir
therapeut
respiratori
viral
diseas
human
wwwalnylamcom
present
studi
also
abl
demonstr
potenti
use
sirna
therapeut
altern
treatment
anim
respiratori
viral
diseas
caus
murin
model
besid
show
effect
sirna
appli
infect
demonstr
sirna
applic
mice
challeng
infect
effect
reduc
clinic
symptom
viru
replic
lung
treat
anim
might
particular
import
case
outbreak
situat
contact
previous
expos
hors
treat
base
result
conceiv
sirna
appli
outbreak
sever
clinic
sign
affect
hors
also
number
affect
hors
magnitud
nasal
shed
could
reduc
result
overal
reduct
viral
load
popul
improv
control
outbreak
effect
intranas
sirna
therapi
need
evalu
target
speci
firm
conclus
drawn
experi
way
address
question
import
fact
complex
pathogenesi
hors
compar
murin
model
intranas
infect
mice
usual
remain
restrict
respiratori
tissu
hors
target
respiratori
tract
pregnant
uteru
central
nervou
system
howev
specif
target
nasal
mucosa
site
initi
invas
replic
model
attenu
diseas
mice
may
predict
hors
set
vitro
vivo
experi
present
studi
design
show
sirna
therapi
target
viral
gene
import
cell
entri
replic
effect
decreas
sever
infect
diseas
possibl
decreas
amount
infecti
viral
particl
produc
upon
infect
also
possibl
decreas
clinic
sign
find
import
implic
term
treat
prevent
outbreak
neither
effect
therapeut
prophylact
measur
import
diseas
current
avail
taken
togeth
potenti
use
rna
interfer
control
infect
intranas
applic
sirna
demonstr
could
prove
effect
mean
control
infect
metaphylact
andor
therapeut
measur
outbreak
situat
rabbit
kidney
cell
maintain
minimum
essenti
medium
mem
mediatech
inc
supplement
fetal
bovin
serum
fb
uml
penicillin
mgml
streptomycin
mediatech
inc
atmospher
wild
type
strain
egfpexpress
propag
cell
small
interf
rna
sirna
encod
gb
encod
helicas
ori
chemic
synthes
ambion
base
sequenc
genbank
sequenc
tabl
sixwel
plate
cell
treat
differ
concentr
sirna
rang
pmol
sirna
complex
lipofectamin
per
manufactur
instruct
invitrogen
ad
cell
total
volum
hour
incub
mlwell
growth
media
ad
incub
h
wash
cell
inocul
plaqu
form
unit
pfu
well
egfpexpress
one
hour
post
infect
pi
medium
remov
infect
cell
overlaid
fresh
medium
supernat
collect
h
pi
cell
fix
formalin
phosphat
buffer
salin
pb
determin
plaqu
size
least
plaqu
per
well
photograph
averag
plaqu
area
determin
use
imag
j
softwar
http
rsbinfonihgovij
determin
extracellular
viral
titer
standard
plaqu
assay
use
essenti
describ
briefli
dilut
supernat
plate
cell
day
pi
cell
fix
formalin
pb
stain
crystal
violet
plaqu
count
evalu
effect
sirna
administr
relat
time
infect
sirna
ad
h
prior
infect
simultan
infect
h
infect
western
blot
analys
perform
exactli
describ
previous
detect
gb
mab
use
dilut
kindli
provid
dr
gp
allen
univers
kentucki
anti
sigma
dilut
use
control
antibodi
antimous
igg
peroxidas
conjug
obtain
immunoresearch
laboratori
use
dilut
sixwel
plate
cell
transfect
sirna
infect
h
later
wildtyp
describ
h
pi
cell
collect
follow
freezethaw
cycl
rna
extract
use
rna
teltest
inc
friendswood
tx
essenti
describ
briefli
dri
rna
pellet
dissolv
rnasefre
water
rna
sampl
dnasetr
turbo
dnafre
kit
accord
manufactur
instruct
ambion
cdna
synthes
use
thermoscript
rtpcr
system
invitrogen
accord
manufactur
instruct
use
random
hexam
thermoscript
revers
transcriptas
qpcr
perform
use
realtim
pcr
system
appli
biosystem
reaction
mixtur
contain
taqman
fast
univers
pcr
master
mix
nm
primer
nm
probe
cdna
total
reaction
volum
paramet
includ
c
sec
activ
taq
polymeras
follow
cycl
sec
sec
primer
probe
use
list
tabl
compar
ct
method
rel
quantit
use
rabbit
endogen
housekeep
gene
anim
experi
perform
accord
us
anim
welfar
act
supervis
cornel
univers
anim
care
use
committe
conduct
previous
describ
modif
threetofour
weekold
femal
balbc
mice
mice
per
group
inocul
vari
concentr
combin
sirna
infect
pfu
strain
describ
tabl
suspens
sirna
without
transfect
reagent
lipofectamin
optimem
pb
respect
mem
administ
intranas
tabl
individu
weight
mice
determin
daili
day
infect
day
day
pi
three
mice
group
euthan
collect
lung
day
pi
left
lobe
homogen
determin
viral
titer
cell
standard
plaqu
assay
right
lobe
fix
formaldehyd
solut
process
histopatholog
analysi
h
estain
lung
section
three
mice
per
group
score
doubleblind
manner
light
microscop
determin
degre
inflamm
bronchiolar
chang
hyperplasia
andor
necrosi
presenc
inclus
bodi
valu
normal
minim
mild
moder
mark
sever
assign
histolog
paramet
score
per
group
comput
total
lung
score
per
group
anoth
set
experi
five
mice
per
group
euthan
day
pi
collect
lung
viral
titrat
addit
determin
viral
genom
load
tissu
qpcr
perform
exactli
previous
describ
student
ttest
pair
data
use
test
differ
data
given
mean
bar
show
standard
deviat
bodi
weight
compar
use
nonparametr
wilcoxonwhitney
kruskal
walli
test
statist
calcul
perform
sa
vs
sa
corpor
cari
nc
